NEW YORK/WASHINGTON (Reuters) – As questions mount over whether health insurer Anthem Inc’s proposed $48 billion purchase of Cigna Corp will win U.S. antitrust approval, an exclusive analysis produced for Reuters suggests the merger could lead to higher costs for large companies offering workplace medical benefits.